Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S-268019 study in children aged 5 to 11 years for prevention of COVID-19
jRCT2011220011Completed
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Jul 2022
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, single-blind trial of S-268019-b in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Shionogi & Co., Ltd. Primary endpoints: Incidence of adverse events, Incidence of adverse reactions and 6 more. Started Jul 2022; status: completed.
02
Drugs
S-268019-b
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2011220011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011220011.